Baudax Bio Inc Revenue Growth Rates (BXRX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Baudax Bio Inc   (NASDAQ: BXRX)
 

BXRX's Revenue Growth by Quarter and Year

Baudax Bio Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BXRX Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December -
3rd Quarter September 0.00
2nd Quarter June 0.03
1st Quarter March 0.01
FY 0.04





BXRX Revenue third quarter 2023 Y/Y Growth Comment
Baudax Bio Inc in the third quarter 2023 recorded of $ 0.00 millions.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 47 other companies have achieved higher Revenue growth. While Baudax Bio Inc ' s Revenue meltdown of -100% ranks overall at the positon no. 284 in the third quarter 2023.


BXRX Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December - -22.5 % 400 % -
3rd Quarter September - -14.29 % 300 % -
2nd Quarter June -90 % 50 % -42.86 % -
1st Quarter March -97.62 % 110 % -61.54 % -
FY   - 17.59 % 5.88 % -

Financial Statements
Baudax Bio Inc 's third quarter 2023 Revenue $ 0.00 millions BXRX's Income Statement
Baudax Bio Inc 's third quarter 2022 Revenue $ 0.24 millions Quarterly BXRX's Income Statement


BXRX Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December - 29.17 % 42.86 % 14.29 %
3rd Quarter September - -20 % 40 % -80 %
2nd Quarter June 200 % -28.57 % 0 % -32.69 %
1st Quarter March -96.77 % 5 % 150 % -
FY (Year on Year)   - 17.59 % 5.88 % -


Back to BXRX Growth rate Comparisons >> Back to BXRX Growth rate Comparisons >>


Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #48
Healthcare Sector #94
Overall #284

Revenue Y/Y Growth Statistics
High Average Low
158.38 % 86.12 % 17.5 %
(Jun 30 2022)   (Dec 31 2022)
Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #48
Healthcare Sector #94
Overall #284
Revenue Y/Y Growth Statistics
High Average Low
158.38 % 86.12 % 17.5 %
(Jun 30 2022)   (Dec 31 2022)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Baudax Bio Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


BXRX's III. Quarter Q/Q Revenue Comment
Recent accomplishment of 0.00 millions by Baudax Bio Inc come out even worse considering the 0.03 millions a quarter before.

Within Major Pharmaceutical Preparations industry Baudax Bio Inc achieved highest sequential Revenue growth. While Baudax Bio Inc 's Revenue growth quarter on quarter, overall rank is .


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


BXRX's III. Quarter Q/Q Revenue Comment
Recent accomplishment of 0.00 millions by Baudax Bio Inc come out even worse considering the 0.03 millions a quarter before.

Within Major Pharmaceutical Preparations industry Baudax Bio Inc achieved highest sequential Revenue growth. While Baudax Bio Inc 's Revenue growth quarter on quarter, overall rank is .


Baudax Bio Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.59 $ 0.86 $ 1.27 $ 1.36
Y / Y Revenue Growth (TTM) - -57.88 % -33.97 % 17.5 % 79.89 %
Year on Year Revenue Growth Overall Ranking # 296 # 184 # 273 # 132 # 268
Seqeuential Revenue Change (TTM) - -31.36 % -32.15 % -6.69 % -3.06 %
Seq. Revenue Growth (TTM) Overall Ranking # 2531 # 1673 # 938 # 342 # 2756


Cumulative Revenue growth Comment
Baudax Bio Inc realized trailing twelve months of $ 0 millions, in the Sep 30 2023, compare to Revenue of $ 1 millions a year ago.

In the Healthcare sector 93 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 184 to 296.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 143
Healthcare Sector # 94
Overall # 296

Revenue TTM Y/Y Growth Statistics
High Average Low
158.38 %
 86.12 %
17.5 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 143
Sector # 394
S&P 500 # 2531
Cumulative Revenue growth Comment
Baudax Bio Inc realized trailing twelve months of $ 0 millions, in the Sep 30 2023, compare to Revenue of $ 1 millions a year ago.

In the Healthcare sector 93 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 184 to 296.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 143
Healthcare Sector # 94
Overall # 296

Revenue TTM Y/Y Growth Statistics
High Average Low
158.38 %
86.12 %
17.5 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 143
Sector # 394
S&P 500 # 2531




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BXRX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue meltdown for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2023
Adaptimmune Therapeutics Plc-0.16%$ -0.164 millions
Procyon Corporation-0.22%$ -0.221 millions
Amedisys Inc-0.31%$ -0.314 millions
Karyopharm Therapeutics Inc -0.38%$ -0.376 millions
Vycor Medical Inc -0.44%$ -0.442 millions
Establishment Labs Holdings Inc -0.50%$ -0.505 millions
Opko Health Inc -0.64%$ -0.639 millions
Integra Lifesciences Holdings Corp-0.72%$ -0.719 millions
Healthcare Services Group Inc -0.75%$ -0.748 millions
Phibro Animal Health Corporation-0.77%$ -0.772 millions
Hologic Inc-0.81%$ -0.808 millions
Bionexus Gene Lab Corp -0.83%$ -0.831 millions
Bellicum Pharmaceuticals Inc -0.89%$ -0.890 millions
Prestige Consumer Healthcare Inc -1.12%$ -1.125 millions
Sharecare Inc -1.13%$ -1.127 millions
Lifevantage Corp-1.14%$ -1.140 millions
Organon and Co -1.17%$ -1.171 millions
Optinose Inc -1.27%$ -1.270 millions
Baxter International Inc -1.72%$ -1.723 millions
Puma Biotechnology Inc -1.73%$ -1.727 millions
Blueprint Medicines Corporation-1.76%$ -1.763 millions
Standard Biotools Inc -1.92%$ -1.918 millions
Pacira Biosciences inc -2.11%$ -2.114 millions
Bristol myers Squibb Company-2.25%$ -2.246 millions
Aurinia Pharmaceuticals Inc -2.27%$ -2.266 millions
Abbott Laboratories-2.56%$ -2.565 millions
Enhabit Inc -2.79%$ -2.785 millions
Novocure Limited-2.81%$ -2.807 millions
Uniqure N v -2.90%$ -2.899 millions
Vaso Corporation-2.92%$ -2.925 millions


About Baudax Bio Inc Revenue Growth Rates (BXRX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Baudax Bio Inc (CIK 1780097).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-23-065200
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Baudax Bio Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.